Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of fondaparinux versus LMWH in NSTE-ACS
ChiCTR1900025366Phase 4Recruiting
- Sponsor
- China Health Promotion Foundation
- Start
- Jul 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux, low molecular weight heparin calcium, ticagrelor and clopidogrel in acute coronary syndrome (ACS), sponsored by China Health Promotion Foundation. Primary endpoints: Death, Major bleeding and 2 more. Started Jul 2019; status: recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calciumticagrelorclopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR1900025366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025366.